{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:53:30Z","timestamp":1790780010017,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.nmd.2021.05.005","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T15:30:41Z","timestamp":1622907041000},"page":"803-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"31","author":[{"given":"Reuven","family":"Tsabari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana","family":"Simchovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Lavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Eliav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Avrahami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Ben-Sasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talya","family":"Dor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.05.005_bib0001","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2021.05.005_bib0002","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of dystrophin disrupts skeletal muscle signaling: roles of ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol Rev"},{"key":"10.1016\/j.nmd.2021.05.005_bib0003","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The pathogenesis and therapy of muscular dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.nmd.2021.05.005_bib0004","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","article-title":"The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.05.005_bib0005","first-page":"13","article-title":"Pulmonary function and clinical correlation in DMD","volume":"30","author":"Mayer","year":"2019","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.nmd.2021.05.005_bib0006","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.nmd.2014.03.006","article-title":"Biomarkers and surrogate endpoints in Duchenne: meeting report","volume":"24","author":"Aartsma-Rus","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.05.005_bib0007","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2021.05.005_bib0008","doi-asserted-by":"crossref","first-page":"E6780","DOI":"10.1073\/pnas.1512968112","article-title":"Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program","volume":"112","author":"Morrison-Nozik","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nmd.2021.05.005_bib0009","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.05.005_bib0010","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2352-4642(18)30140-8","article-title":"Genetic therapies for inherited neuromuscular disorders","volume":"2","author":"Scoto","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.nmd.2021.05.005_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003222","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study","volume":"17","author":"Smith","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.nmd.2021.05.005_bib0012","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.nmd.2021.05.005_bib0013","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jsbmb.2014.03.003","article-title":"An overview of current and emerging SERMs","volume":"143","author":"Komm","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.nmd.2021.05.005_bib0014","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ajpath.2012.10.018","article-title":"The anticancer drug tamoxifen counteracts the pathology in a mouse model of Duchenne muscular dystrophy","volume":"182","author":"Dorchies","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2021.05.005_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy","volume":"8","author":"McGreevy","year":"2015","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.nmd.2021.05.005_bib0016","doi-asserted-by":"crossref","first-page":"e61165","DOI":"10.1371\/journal.pone.0061165","article-title":"Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis","volume":"8","author":"Loureiro","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.nmd.2021.05.005_bib0017","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/S0960-8966(02)00095-0","article-title":"Pharmacological control of cellular calcium handling in dystrophic skeletal muscle","volume":"12","author":"Ruegg","year":"2002","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.05.005_bib0018","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1002\/jcp.25049","article-title":"Tamoxifen Inhibits TGF-\u03b2-mediated activation of myofibroblasts by blocking non-smad signaling through ERK1\/2","volume":"230","author":"Carthy","year":"2015","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.nmd.2021.05.005_bib0019","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/WCO.0b013e328364fbaf","article-title":"Pharmacological prospects in the treatment of Duchenne muscular dystrophy","volume":"26","author":"Ruegg","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nmd.2021.05.005_bib0020","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1038\/s41467-018-07057-5","article-title":"Tamoxifen therapy in a murine model of myotubular myopathy","volume":"9","author":"Maani","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmd.2021.05.005_bib0021","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1038\/s41467-018-07058-4","article-title":"Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy","volume":"9","author":"Gayi","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmd.2021.05.005_bib0022","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1515\/JPEM.2008.21.5.449","article-title":"Long-term follow-up of tamoxifen treatment in adolescents with gynecomastia","volume":"21","author":"Derman","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.nmd.2021.05.005_bib0023","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1542\/peds.2005-0577","article-title":"The use of tamoxifen to improve height potential in short pubertal boys","volume":"116","author":"Kreher","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.nmd.2021.05.005_bib0024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpeds.2004.03.057","article-title":"Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia","volume":"145","author":"Lawrence","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2021.05.005_bib0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10928-019-09642-7","article-title":"Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy","volume":"46","author":"Conrado","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.nmd.2021.05.005_bib0026","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/WCO.0000000000000470","article-title":"Respiratory involvement in neuromuscular disorders","volume":"30","author":"Boentert","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nmd.2021.05.005_bib0027","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000435881","article-title":"Tamoxifen improves final height prediction in girls with McCune-albright syndrome: a long follow-up","volume":"84","author":"de G Buff Passone","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.nmd.2021.05.005_bib0028","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00002512-199608050-00002","article-title":"Tamoxifen in postmenopausal women a safety perspective","volume":"8","author":"Robinson","year":"1996","journal-title":"Drugs Aging"},{"key":"10.1016\/j.nmd.2021.05.005_bib0029","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.celrep.2019.06.025","article-title":"Estrogen regulates the satellite cell compartment in females","volume":"28","author":"Collins","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.nmd.2021.05.005_bib0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.stemcr.2020.07.017","article-title":"Estrogen receptor \u03b2 controls muscle growth and regeneration in young female mice","volume":"15","author":"Seko","year":"2020","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.nmd.2021.05.005_bib0031","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1530\/JOE-15-0476","article-title":"Estrogens maintain skeletal muscle and satellite cell functions","volume":"229","author":"Kitajima","year":"2016","journal-title":"J Endocrinol"},{"key":"10.1016\/j.nmd.2021.05.005_bib0032","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.2017.73.3246","article-title":"First-in-human phase i study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nmd.2021.05.005_bib0033","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s13063-019-3740-6","article-title":"Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial","volume":"20","author":"Nagy","year":"2019","journal-title":"Trials"}],"updated-by":[{"DOI":"10.1016\/j.nmd.2022.01.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000}}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621001309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621001309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T04:13:35Z","timestamp":1679544815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621001309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0960896621001309"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.05.005","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.nmd.2022.01.007","asserted-by":"object"}]},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}